traveltech_sara said:The FLOW trial results on renal function and renal outcomes: semaglutide 1.0mg reduced the composite kidney outcome by 24% (HR 0.76, p=0.0003) in CKD…
This matches mine closely enough to be worth saying so out loud.
One thing that is still open after TrialNerd_Beth’s answer:
Whether anyone has held at a sub-maximal dose long term and kept the result, or whether the maintenance data only exists at 2.4mg?
Dr.PulmRoch said:Kidney function labs on renal function — good news for anyone concerned about renal effects: Marker Baseline Month 6 Ref Range eGFR 75 88 >60…
GFR trending upward on renal function — encouraging for those with mild CKD concerns:
Baseline eGFR: 71 → Month 6: 85 → Month 12: 85
The FLOW trial confirmed renal benefits of semaglutide: 24% reduction in kidney disease progression. My nephrologist is now actively recommending GLP-1 therapy for appropriate CKD patients. This could be a paradigm shift in nephrology.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsDr.PulmRoch said:Kidney function labs on renal function — good news for anyone concerned about renal effects: Marker Baseline Month 6 Ref Range eGFR 75 88 >60…
That holds where the measurement is reliable. Where it is noisy — and a lot of what gets tracked here is noisy — the same reasoning produces confident nonsense.
Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Report rather than reply if it drifts again.